Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 15329413

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306-11 15329413

Y1092-p - EGFR (human)

▲

Orthologous residues

EGFR (human): Y1092‑p, EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody

Relevant cell lines - cell types - tissues: 293T (epithelial)

Cellular systems studied: cell lines

Species studied: human

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
EGF				increase
gefitinib				decrease
erlotinib				decrease

Home \| Curator Login	With enhanced literature mining using Linguamatics I2E		Produced by 3rd Millennium \| Design by Digizyme
			©2003-2013 Cell Signaling Technology, Inc.